{"created":"2025-06-17T06:30:05.389732+00:00","id":2040745,"links":{},"metadata":{"_buckets":{"deposit":"4501cf6c-54de-4b3d-ad5f-4cc1dbbcd21d"},"_deposit":{"created_by":79,"id":"2040745","owner":"79","owners":[79],"pid":{"revision_id":0,"type":"depid","value":"2040745"},"status":"published"},"_oai":{"id":"oai:hiroshima.repo.nii.ac.jp:02040745","sets":["1730444907710"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests","subitem_title_language":"ja"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kinoshita, Yasuyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Taguchi, Akira","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Yamasaki, Fumiyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Onishi, Shumpei","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tominaga,  Atsushi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Horie, Nobutaka","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"embargoed access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_f1cf"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s11102-024-01487-9","subitem_rights_language":"en"},{"subitem_rights":"This is not the published version. Please cite only the published version.","subitem_rights_language":"en"},{"subitem_rights":"この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。","subitem_rights_language":"ja"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Acromegaly","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Growth hormone","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Insulin-like growth factor-1","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Discordance","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Discrepancy","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Purpose\nAcromegaly patients occasionally achieve either of the remission criterion of IGF-1 or GH level postoperatively; however, treatment for patients with discordant IGF-1 and GH levels remains unclear. This study aimed to clarify the clinical courses and features of postoperative patients with normal IGF-1 and high GH levels and support their management.\n\nMethods\nOverall, 110 acromegaly patients underwent initial surgery and a 75-g oral glucose tolerance test (OGTT) 3 months postoperatively. Of the 110, 23 patients with normal IGF-1 and nadir GH levels of ≥ 0.4 µg/L on OGTT (high-GH group) were categorized into three subtypes based on their repeated examinations thereafter: late-remission type (nadir GH level on OGTT of < 0.4 µg/L later), recurrence type (elevated IGF-1 and GH levels later), and persistent type (normal IGF-1 levels and constantly high nadir GH levels on OGTTs).\n\nResults\nProportion of patients in the high-GH group was 23.6%, and they were distributed as follows: late-remission type (n = 10), recurrence type (n = 5), and persistent type (n = 8). There were significantly more women (P = 0.0178) than men in the late-remission type, and patients in the persistent type had significantly larger tumors (P = 0.0110) and higher preoperative GH levels (P = 0.0018) than those that achieved complete remission 3 months postoperatively.\n\nConclusion\nCareful monitoring without additional medications is recommended at first in acromegaly patients with normal IGF-1 and high GH levels considering the possibility of recurrence in the future.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"Springer","subitem_publisher_language":"en"}]},"item_1617186660861":{"attribute_name":"Date","attribute_value_mlt":[{"subitem_date_issued_datetime":"2025-12-26","subitem_date_issued_type":"Available"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186901218":{"attribute_name":"Funding Reference","attribute_value_mlt":[{"subitem_award_numbers":{"subitem_award_number":"23K06697","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23K06697/"},"subitem_award_titles":[{"subitem_award_title":"Pit-NETにおけるsmall RNAを用いた診断バイオマーカーの確立と核酸医薬への応用","subitem_award_title_language":"ja"}],"subitem_funder_identifiers":{"subitem_funder_identifier_type":"Crossref Funder","subitem_funder_identifier_type_uri":"https://doi.org/10.13039/501100001691"},"subitem_funder_names":[{"subitem_funder_name":"日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2024-12-26","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicNumberOfPages":"9","bibliographicPageStart":"none","bibliographicVolumeNumber":"28","bibliographic_titles":[{"bibliographic_title":"Pituitary","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s11102-024-01487-9","subitem_relation_type_select":"DOI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2025-12-26"}],"fileDate":[{"fileDateType":"Available","fileDateValue":"2025-12-26"}],"filename":"Pituitary_28_4.pdf","filesize":[{"value":"902 KB"}],"format":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2040745/files/Pituitary_28_4.pdf"},"version_id":"47aaf715-386c-4c35-91e0-0c5ffd0e6fc5"}]},"item_1732772494514":{"attribute_name":"備考","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"The full-text file will be made open to the public on 26 December 2025 in accordance with publisher's 'Terms and Conditions for Self-Archiving'"}]},"item_title":"Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests","item_type_id":"40036","owner":"79","path":["1730444907710"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2025-06-17"},"publish_date":"2025-06-17","publish_status":"0","recid":"2040745","relation_version_is_last":true,"title":["Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests"],"weko_creator_id":"79","weko_shared_id":-1},"updated":"2025-06-17T06:53:22.234977+00:00"}